ERBB2 and breast carcinoma: The COMPASS-HER2 trial (NCT04266249) is currently studying adjuvant T-DM1 in combination with tucatinib versus placebo for early-stage, high-risk HER2-positive breast cancer patients with residual disease after neoadjuvant HER2-directed therapy.